Replies to post #224644 on Biotech Values

[DewDiligence]

SBPH—The Twitter thread you cited is quite technical. I get the issue of nucleoside phosphorylation (e.g. #msg-42396728, #msg-64569966, #msg-64570180); however, my understanding is that the second and third phosphorylation steps are not as finicky as the first, so I might not fully gree with John Tucker's tweets in the thread you referenced.

p.s. I plan to listen to the SBPH CC replay over the weekend.

[DewDiligence]

SBPH addendum: Listened to the webcast and studies the CC slides. I don't see any particular reason to be optimistic about the outcomes of the phase-2b trials (just getting underway) other than in showing Inarigivir could have a place as salvage therapy for patients with nuke resistance. But this is not the big market that other HBV players are pursuing.

[DewDiligence]

SBPH—6/30/19 cash=$49.2M—2Q19 burn=($15.2M):

https://www.globenewswire.com/news-release/2019/07/31/1895158/0/en/Spring-Bank-Pharmaceuticals-Reports-Second-Quarter-2019-Financial-and-Operational-Results-and-Provides-Business-Development-Update.html

My view of the HBV program in #msg-148213028 still holds.